<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20378" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atopic Dermatitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kolb</surname>
            <given-names>Logan</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ferrer-Bruker</surname>
            <given-names>Sarah J.</given-names>
          </name>
          <aff>VCOM/Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Logan Kolb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Ferrer-Bruker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20378.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atopic dermatitis (AD), which is a specific form of eczema, is the most common chronic inflammatory skin disease. Atopic dermatitis has a complex etiology including genetic and environmental factors which lead to abnormalities in the epidermis and the immune system. This activity reviews the causes, pathophysiology and presentation of atopic dermatitis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of atopic dermatitis.</p></list-item><list-item><p>Review the presentation of a patient with atopic dermatitis.</p></list-item><list-item><p>Outline the treatment and management options available for atopic dermatitis</p></list-item><list-item><p>Explain the interprofessional team strategies for improving care and outcomes in patients with atopic dermatitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20378&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20378">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20378.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Atopic dermatitis (AD), which is a specific form of eczema, is the most common chronic inflammatory skin disease.<xref ref-type="bibr" rid="article-20378.r1">[1]</xref><xref ref-type="bibr" rid="article-20378.r2">[2]</xref><xref ref-type="bibr" rid="article-20378.r3">[3]</xref></p>
        <p>This chronic disorder associated with pruritus usually starts in infancy and presents with dry skin, eczematous lesions and lichenification. It is believed that AD is associated with other IgE associated disorders like allergic rhinitis, asthma, and food allergies. AD has significant morbidity and it appears that the prevalence of the disorder has been increasing over the past few decades.</p>
      </sec>
      <sec id="article-20378.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Atopic dermatitis has a complex etiology including genetic and environmental factors which lead to abnormalities in the epidermis and the immune system. Atopic dermatitis&#x000a0;is part of the atopic triad (atopic dermatitis, allergic rhinoconjunctivitis, and asthma) which may start simultaneously or in succession in what is known as&#x000a0;the "atopic march." Patients with the atopic triad have a defective barrier of the skin, upper respiratory, and lower respiratory tract which leads to their symptomatology.&#x000a0;If one parent is atopic, there is more than a 50% chance that their offspring will develop atopic symptoms. If both parents are affected, up to 80% of offspring will be affected. Genetic alterations include loss of function mutations of filaggrin (Filament <bold>Ag</bold>gregating Prote<bold>in</bold>), an epidermal protein that is broken down into natural moisturization factor. Filaggrin mutations are present in up to 30% of atopic dermatitis&#x000a0;patients and may also predispose patients to ichthyosis vulgaris, allergic rhinitis, and keratosis pilaris. Food hypersensitivity may also cause or exacerbate atopic dermatitis in&#x000a0;10% to 30% of patients. Ninety percent of such reactions or flares are caused by eggs, milk, peanuts, soy, and wheat.<xref ref-type="bibr" rid="article-20378.r4">[4]</xref><xref ref-type="bibr" rid="article-20378.r5">[5]</xref></p>
        <p>Recent studies indicate that there may be an association between smoking and adult-onset&#x000a0;AD.</p>
      </sec>
      <sec id="article-20378.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Atopic dermatitis is seen in approximately 10% to 30% of children and 2% to 10% of adults in developed countries. This prevalence has increased two to three-fold in recent decades. Atopic dermatitis&#x000a0;has a higher incidence at higher latitudes, which may be related to decreased sun exposure and lower humidity levels. Atopic dermatitis&#x000a0;is divided into three subsets based on the age of onset:</p>
        <list list-type="order">
          <list-item>
            <p>Early-onset atopic dermatitis&#x000a0;(birth to 2 years old): &#x000a0;most common type of atopic dermatitis, with approximately 60% of cases starting by age 1. Sixty percent of cases resolve by 12 years old</p>
          </list-item>
          <list-item>
            <p>Late-onset atopic dermatitis: &#x000a0;symptoms begin after the onset of puberty</p>
          </list-item>
          <list-item>
            <p>Senile onset atopic dermatitis: an unusual subset with onset in patients older than 60 years old.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20378.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Atopic dermatitis patients have&#x000a0;a defective skin barrier that is&#x000a0;susceptible to xerosis and environmental irritants and allergens that lead to inflammation, pruritus, and the classic clinical findings of atopic dermatitis. The barrier defect may be caused in part by decreased levels of ceramides, which are sphingolipids in the stratum corneum which play a role in the skin's barrier function and prevent transepidermal water loss. The defective skin barrier allows irritants and allergens to penetrate the skin and cause inflammation via an overactive Th2 response (with increased IL-4, IL-5 cytokines) in acute lesions and Th1 response (with IFN-gamma and IL-12) in chronic lesions. Scratching of the skin also stimulates keratinocytes to release inflammatory cytokines such as TNF-alpha, IL-1, and IL-6. Decreased anti-microbial peptides (human beta-defensins, cathelicidins) in the epidermis of atopic patients also contribute to <italic toggle="yes">Staphylococcus aureus</italic> colonization seen in more than 90% of atopic dermatitis&#x000a0;patients.&#x000a0;<italic toggle="yes">S. aureus</italic> may worsen the inflammation of atopic dermatitis&#x000a0;lesions and lead to secondary infection and impetiginization.&#x000a0;<xref ref-type="bibr" rid="article-20378.r6">[6]</xref><xref ref-type="bibr" rid="article-20378.r7">[7]</xref></p>
        <p>In AD, there is significant water loss across the epidermis, but why there is dysregulation of the epithelial barrier is not fully understood. It is believed that filaggrin, which is critical for epithelial integrity, may be dysfunctional.</p>
      </sec>
      <sec id="article-20378.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A practitioner should take a patient's history and focus on&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset and distribution of lesions</p>
          </list-item>
          <list-item>
            <p>The severity of pruritus (e.g., keeping patient awake at night)</p>
          </list-item>
          <list-item>
            <p>Family and/or personal history of the atopic triad</p>
          </list-item>
          <list-item>
            <p>Presence of contact allergens</p>
          </list-item>
          <list-item>
            <p>The presence of triggers including allergens (e.g., dust mites, animal dander), hot showers/sweating, soaps, fragrances, food hypersensitivities, and synthetic fabrics such as polyester.</p>
          </list-item>
        </list>
        <p>Classic physical exam findings depend on age group. Infants develop edematous papules and plaques that may have vesicles or crust on the scalp, face, and extensor extremities. Infants rarely have atopic dermatitis&#x000a0;lesions affecting the diaper area but may be susceptible to other causes of diaper dermatitis such as candida or seborrheic dermatitis. Atopic dermatitis&#x000a0;children classically have less exudative patches and plaques on antecubital and popliteal fossae; adults have chronic lichenified (enhanced skin markings) lesions that have a predilection for hands. Individual lesions may also be further classified into acute (edematous, erythematous papules and plaques and/or vesicles/crusting), subacute (erythema, scale, variable crusting), or chronic (thick plaques with lichenification and scale) stages.</p>
      </sec>
      <sec id="article-20378.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Atopic dermatitis is typically a clinical diagnosis given the classic distribution of lesions in each age group. The presence of associated findings (e.g., keratosis pilaris) may facilitate diagnosis. A biopsy will show an eczematous pattern. In childhood cases that are&#x000a0;recalcitrant to treatment, fluorescent enzyme immunoassays or skin prick testing can be performed to detect immunoglobulin E (IgE) antibodies against specific allergens, which may or may not be a clinically relevant exacerbating factor.<xref ref-type="bibr" rid="article-20378.r8">[8]</xref><xref ref-type="bibr" rid="article-20378.r9">[9]</xref></p>
      </sec>
      <sec id="article-20378.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The four major components of treatment include&#x000a0;trigger avoidance, daily skin care, anti-inflammatory therapy, and other complementary modalities.</p>
        <p>Daily skin care includes the application of emollients twice daily, with the application within three minutes of exiting lukewarm shower or bath to prevent skin drying. Ointments are the most occlusive but may be more greasy. Topical steroids, which should be applied before emollients to "lock-in" their effect, are first-line agents for acute flares. The potency should be strong enough to control a flare quickly, and consideration should be given for tapering every other day and for maintenance therapy twice weekly (e.g., weekends) in the usual areas of involvement. Reversible side effects of steroid use include skin atrophy and telangiectasia.</p>
        <p>Sensitive areas (including the intertriginous areas of the axilla and groin, in addition to the face) may require topical nonsteroidal agents including calcineurin inhibitors such as tacrolimus and pimecrolimus. Newer non-steroidal agents include crisaborole, which exerts its effect by blocking PDE-4. When atopic dermatitis&#x000a0;is not controlled with topical agents, systemic agents include phototherapy (ultraviolet (UV) A, UVB, and narrow-band UVB), cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate.</p>
        <p>&#x000a0;A newly FDA-approved biologic therapy is dupilumab, which is a monoclonal antibody that blocks the IL-4 receptor and thus the effect of IL-4 and IL-13. &#x000a0;Other complementary therapies include bleach baths (0.5 cup bleach in full 40 gallon tub) one to two times weekly to decrease <italic toggle="yes">S. aureus</italic> colonization, low allergen maternal diets during breastfeeding, and probiotic and prebiotic use in pregnant mothers and at-risk infants which has shown 50% decreased frequency of atopic dermatitis&#x000a0;at ages 1 to 4 years old compared to placebo.<xref ref-type="bibr" rid="article-20378.r10">[10]</xref><xref ref-type="bibr" rid="article-20378.r11">[11]</xref><xref ref-type="bibr" rid="article-20378.r12">[12]</xref></p>
        <p>Recently Crisaborole topic ointment was approved for mild to moderate AD. The drug is a phosphodiesterase inhibitor and shown to improve skin symptoms.</p>
        <p>Some patients may benefit from probiotics; it is believed that the bacterial products may enhance the immune system and prevent the development of allergic IgE antibody response. Further, probiotics are recommended during pregnancy and in breast feeding women.</p>
        <p>Numerous studies show that bleach baths may help relieve the symptoms of AD by lowering the risk of superinfection with bacteria.</p>
      </sec>
      <sec id="article-20378.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Allergic contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Lichen simplex</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Scabies</p>
          </list-item>
          <list-item>
            <p>Tinea</p>
          </list-item>
          <list-item>
            <p>Seborrheic</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20378.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>Guidelines on the use of cyclosporine</p>
        <list list-type="order">
          <list-item>
            <p>Cyclosporine has been approved for use in AD under the following conditions:</p>
          </list-item>
          <list-item>
            <p>The patient is older than age 16</p>
          </list-item>
          <list-item>
            <p>Continuous treatment is only done if appropriate monitoring is undertaken</p>
          </list-item>
          <list-item>
            <p>Intermittent doses of up to 16 weeks are recommended in most patients</p>
          </list-item>
          <list-item>
            <p>The dose should be titrated to lower renal toxicity</p>
          </list-item>
          <list-item>
            <p>If hypertension develops, the dose should be reduced or discontinued</p>
          </list-item>
          <list-item>
            <p>If an infection develops, reduce the dose of cyclosporine and manage the infection</p>
          </list-item>
          <list-item>
            <p>All patients should be educated about symptoms of infections and when to seek help</p>
          </list-item>
          <list-item>
            <p>Patients need to be monitored for nonmelanoma skin cancer</p>
          </list-item>
          <list-item>
            <p>Cyclosporine should not be used at the same time as phototherapy</p>
          </list-item>
          <list-item>
            <p>Monitor serum lipid levels</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20378.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overall, many patients with AD do improve with time. However, at the same time patients with AD may also have allergic rhinitis and asthma, which may not improve. In most cases of childhood-onset AD, the disorder persists for decades. The condition has relapses and remissions; relapses often require the use of medications. Individuals who are continuously exposed to smoke, tobaccos, pet dander, fumes, pollen, soap, detergent, and wool will have continual symptoms and the overall quality of life is poor.</p>
        <p>Persistent and recurrent itching not only is irritating but is costly to manage. A well-known complication of AD is Kaposi varicelliform eruption,&#x000a0; that is linked to a primary herpes infection. The vesicular lesions appear in the eczematous area and can quickly spread to healthy skin. Treatment with acyclovir can help lower the morbidity.</p>
        <p>Patients with AD are also prone to skin infections with Staphylococcus and streptococcus.</p>
      </sec>
      <sec id="article-20378.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Kaposi varicelliform eruption</p>
          </list-item>
          <list-item>
            <p>Bacterial infection</p>
          </list-item>
          <list-item>
            <p>Uriticaria</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20378.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should wear cotton garments and avoid wool. In addiion, the temperature in the home should be on the cooler side as it may help decrease sweating and itching. A humidifier is recommended to prevent drying of the skin. Foods that trigger AD symptoms should be avoided.</p>
      </sec>
      <sec id="article-20378.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Treatment and management of atopic dermatitis&#x000a0;should start with education of the patient and/or parents of the chronic nature of the disease and importance of maintenance therapy, which improves&#x000a0;the epidermal barrier and prevents sensitization to allergens and possible&#x000a0;prevention of atopic dermatitis.</p>
      </sec>
      <sec id="article-20378.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Atopic dermatitis is a chronic skin disorder that can adversely affect the quality of life. While the condition can be managed with medical therapy, there are also non-medical remedies that can make a big difference in the quality of life. Both the pharmacist and nurse can play a vital role in educating the patient on nonmedical remedies to manage atopic dermatitis. The patient should be educated on wearing soft clothing- preferably cotton and avoid wool. The home temperatures should be kept low because the heat can cause sweating and exacerbation of the irritation. A humidifier should&#x000a0;be used to&#x000a0;prevent dryness in the home. All garments should be washed with a mild detergent with no fabric softener or bleach. When going outdoors, ample sunscreen and moisturizer should be applied. The patient should keep a diary of all the foods and avoid foods that trigger the attacks. The patient should avoid activities that cause excess diaphoresis. Finally, patients who have asthma should be compliant with their medications and avoid allergens.<xref ref-type="bibr" rid="article-20378.r13">[13]</xref><xref ref-type="bibr" rid="article-20378.r14">[14]</xref>&#x000a0;(level II)</p>
        <p>
<bold>Outcome</bold>
</p>
        <p>The majority of patients with atopic dermatitis do&#x000a0;improve with age. About 30% of patients will develop allergic rhinitis, and 30% will develop asthma. A long-term&#x000a0;study that evaluated patients with Atopic Dermatitis indicates that mild to moderate symptoms often persist for a decade or more. And about 80% of these patients will need topical medications to control the symptoms. Symptoms relief is usually seen after the 2nd decade of life, but this also means a drastic change in lifestyle that includes avoiding all triggers like tobacco, pet dander, wool, and certain soaps. Atopic dermatitis may not be life-threatening, but it can seriously affect the quality of life. The constant dryness and itching of skin not only leads to a high financial burden and often requires multiple hospital visits. <xref ref-type="bibr" rid="article-20378.r1">[1]</xref><xref ref-type="bibr" rid="article-20378.r15">[15]</xref>(Level V)</p>
      </sec>
      <sec id="article-20378.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20378&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20378">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/atopic-dermatitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20378">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20378/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20378">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20378.s17">
        <fig id="article-20378.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Atopic dermatitis Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="atopic__dermatitis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20378.s18">
        <fig id="article-20378.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Kaposi Varicelliform Eruption. Kaposi varicelliform eruption, also called eczema herpeticum, refers to a disseminated skin infection due to a virus that usually leads to localized vesicular eruptions that occur in a patient with an underlying cutaneous disease.&#x000a0;Although rare, it is a potentially life-threatening disorder. Herpes simplex virus is considered the primary causative agent. Contributed by&#x000a0;O Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kapsosi__Varicelliform" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20378.s19">
        <title>References</title>
        <ref id="article-20378.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaworski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Boguniewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Tofte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eichenfield</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>821</fpage>
            <page-range>821-838</page-range>
            <pub-id pub-id-type="pmid">30168085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giavina-Bianchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giavina-Bianchi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Systemic Treatment for Severe Atopic Dermatitis.</article-title>
            <source>Arch Immunol Ther Exp (Warsz)</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-78</page-range>
            <pub-id pub-id-type="pmid">30159581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drucker</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jabbar-Lopez</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>ZZN</given-names>
              </name>
              <name>
                <surname>Arents</surname>
                <given-names>BWM</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spuls</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>K&#x000fc;ster</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Flohr</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis.</article-title>
            <source>BMJ Open</source>
            <year>2018</year>
            <month>Aug</month>
            <day>29</day>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>e023061</fpage>
            <pub-id pub-id-type="pmid">30158235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveira</surname>
                <given-names>ADT</given-names>
              </name>
              <name>
                <surname>Sodr&#x000e9;</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Abad</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Saintive</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavalcante</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Piciani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Oral Aspects Identified in Atopic Dermatitis Patients: A Literature Review.</article-title>
            <source>Open Dent J</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>424</fpage>
            <page-range>424-434</page-range>
            <pub-id pub-id-type="pmid">29988222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>N&#x000f8;rgaard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thyssen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zachariae</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hommel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rytter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Skin Problems Associated with Insulin Pumps and Sensors in Adults with Type 1 Diabetes: A Cross-Sectional Study.</article-title>
            <source>Diabetes Technol Ther</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>475</fpage>
            <page-range>475-482</page-range>
            <pub-id pub-id-type="pmid">29893593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murota</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Sweat in the pathogenesis of atopic dermatitis.</article-title>
            <source>Allergol Int</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>455</fpage>
            <page-range>455-459</page-range>
            <pub-id pub-id-type="pmid">30082151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hulshof</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Overbeek</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wyllie</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>MLJN</given-names>
              </name>
              <name>
                <surname>Bogaert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Jager</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Knippels</surname>
                <given-names>LMJ</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>EAM</given-names>
              </name>
              <name>
                <surname>van Aalderen</surname>
                <given-names>WMC</given-names>
              </name>
              <name>
                <surname>Garssen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van't Land</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sprikkelman</surname>
                <given-names>AB</given-names>
              </name>
              <collab>Clinical Study Group</collab>
            </person-group>
            <article-title>Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis.</article-title>
            <source>Front Immunol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>630</fpage>
            <pub-id pub-id-type="pmid">29966024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Allergic Contact Dermatitis Evaluation: Strategies for the Preschooler.</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">30069607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batmaz</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Laboratory and severity evaluation of pediatric atopic dermatitis and moisturizer response in different phenotypes.</article-title>
            <source>Allergol Immunopathol (Madr)</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>571</fpage>
            <page-range>571-577</page-range>
            <pub-id pub-id-type="pmid">29980402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ari&#x000eb;ns</surname>
                <given-names>LFM</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>van der Schaft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garritsen</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Thijs</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>de Bruin-Weller</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy.</article-title>
            <source>Ther Adv Chronic Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>159</fpage>
            <page-range>159-170</page-range>
            <pub-id pub-id-type="pmid">30181845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ulrik</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Agner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Association between Atopic Dermatitis and the Metabolic Syndrome: A Systematic Review.</article-title>
            <source>Dermatology</source>
            <year>2018</year>
            <volume>234</volume>
            <issue>3-4</issue>
            <fpage>79</fpage>
            <page-range>79-85</page-range>
            <pub-id pub-id-type="pmid">30110673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbarot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Christen-Zaech</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deleuran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fink-Wagner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gieler</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Girolomoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Czarnecka-Operacz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmid-Grendelmeier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szalai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ta&#x000ef;eb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torrelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Werfel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
              <collab>European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients&#x02019; Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS)</collab>
            </person-group>
            <article-title>Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part&#x000a0;II.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>850</fpage>
            <page-range>850-878</page-range>
            <pub-id pub-id-type="pmid">29878606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastogi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Singam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>1028</fpage>
            <page-range>1028-1033.e6</page-range>
            <pub-id pub-id-type="pmid">30053491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Sach</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Cowdell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lawton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Haines</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burrows</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Llewellyn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Guiness</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gribbin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wake</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial.</article-title>
            <source>Health Technol Assess</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>16</issue>
            <fpage>1</fpage>
            <page-range>1-260</page-range>
            <pub-id pub-id-type="pmid">28409557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20378.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Napolitano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marasca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fabbrocini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patruno</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Adult atopic dermatitis: new and emerging therapies.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>867</fpage>
            <page-range>867-878</page-range>
            <pub-id pub-id-type="pmid">30073901</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
